Brief: Seres Therapeutics FY EPS USD 0.64
12/03/2026 11:00
Mar 12 (Reuters) - Seres Therapeutics FY collaboration revenue USD 789 thousand. FY operating expenses USD 94.76 million FY net income USD 5.696 million FY operating income USD -93.971 million
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47